In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics

Iryna Pinchuk, P. Bressollier, B. Verneuil, B. Fenet, I. B. Sorokulova, F. Mégraud, M. C. Urdaci

Research output: Contribution to journalArticle

155 Citations (Scopus)

Abstract

A limited number of antibiotics can be used against Helicobacter pylori infection, and resistance jeopardizes the success of treatment. Therefore, a search for new agents is warranted. The use of probiotics to enhance gastrointestinal health has been proposed for many years, but the scientific basis of the prophylactic and therapeutic actions of probiotics has not yet been clearly delineated. Probiotic strain Bacillus subtilis 3, whose safety has previously been demonstrated, is known to have antagonistic properties against species of the family Enterobacteriaceae. In the present study, it was also found to inhibit H. pylori. The anti-H, priori activity present in the cell-free supernatant was not related to pH or organic acid concentration. It was heat stable and protease insensitive. At least two antibiotics, detected by thin-layer chromatography (Rf values, 0.47 and 0.85, respectively) and confirmed by high-performance liquid chromatographic analysis, were found to be responsible for this anti-H, pylori activity. All H. priori strains tested were sensitive to both compounds. One of these compounds was identified as amicoumacin A, an antibiotic with anti-inflammatory properties. MICs for H. priori determined in solid and liquid media ranged between 1.7 and 6.8 μg/ml and 0.75 and 2.5 μg/ml, respectively. The underestimation of MICs determined in solid medium may be due to physicochemical instability of the antibiotic under these test conditions. An additive effect between amicoumacin A and the nonamicoumacin antibiotic against H. pylori was demonstrated.

Original languageEnglish (US)
Pages (from-to)3156-3161
Number of pages6
JournalAntimicrobial Agents and Chemotherapy
Volume45
Issue number11
DOIs
StatePublished - 2001
Externally publishedYes

Fingerprint

Probiotics
Bacillus subtilis
Helicobacter pylori
Anti-Bacterial Agents
Pylorus
Helicobacter Infections
Enterobacteriaceae
Thin Layer Chromatography
Peptide Hydrolases
Anti-Inflammatory Agents
Hot Temperature
High Pressure Liquid Chromatography
In Vitro Techniques
Safety
Acids
Health
amicoumacin A

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. / Pinchuk, Iryna; Bressollier, P.; Verneuil, B.; Fenet, B.; Sorokulova, I. B.; Mégraud, F.; Urdaci, M. C.

In: Antimicrobial Agents and Chemotherapy, Vol. 45, No. 11, 2001, p. 3156-3161.

Research output: Contribution to journalArticle

Pinchuk, Iryna ; Bressollier, P. ; Verneuil, B. ; Fenet, B. ; Sorokulova, I. B. ; Mégraud, F. ; Urdaci, M. C. / In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics. In: Antimicrobial Agents and Chemotherapy. 2001 ; Vol. 45, No. 11. pp. 3156-3161.
@article{403ad3f44ec640cca223ebb3b6331024,
title = "In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics",
abstract = "A limited number of antibiotics can be used against Helicobacter pylori infection, and resistance jeopardizes the success of treatment. Therefore, a search for new agents is warranted. The use of probiotics to enhance gastrointestinal health has been proposed for many years, but the scientific basis of the prophylactic and therapeutic actions of probiotics has not yet been clearly delineated. Probiotic strain Bacillus subtilis 3, whose safety has previously been demonstrated, is known to have antagonistic properties against species of the family Enterobacteriaceae. In the present study, it was also found to inhibit H. pylori. The anti-H, priori activity present in the cell-free supernatant was not related to pH or organic acid concentration. It was heat stable and protease insensitive. At least two antibiotics, detected by thin-layer chromatography (Rf values, 0.47 and 0.85, respectively) and confirmed by high-performance liquid chromatographic analysis, were found to be responsible for this anti-H, pylori activity. All H. priori strains tested were sensitive to both compounds. One of these compounds was identified as amicoumacin A, an antibiotic with anti-inflammatory properties. MICs for H. priori determined in solid and liquid media ranged between 1.7 and 6.8 μg/ml and 0.75 and 2.5 μg/ml, respectively. The underestimation of MICs determined in solid medium may be due to physicochemical instability of the antibiotic under these test conditions. An additive effect between amicoumacin A and the nonamicoumacin antibiotic against H. pylori was demonstrated.",
author = "Iryna Pinchuk and P. Bressollier and B. Verneuil and B. Fenet and Sorokulova, {I. B.} and F. M{\'e}graud and Urdaci, {M. C.}",
year = "2001",
doi = "10.1128/AAC.45.11.3156-3161.2001",
language = "English (US)",
volume = "45",
pages = "3156--3161",
journal = "Antimicrobial Agents and Chemotherapy",
issn = "0066-4804",
publisher = "American Society for Microbiology",
number = "11",

}

TY - JOUR

T1 - In vitro anti-Helicobacter pylori activity of the probiotic strain Bacillus subtilis 3 is due to secretion of antibiotics

AU - Pinchuk, Iryna

AU - Bressollier, P.

AU - Verneuil, B.

AU - Fenet, B.

AU - Sorokulova, I. B.

AU - Mégraud, F.

AU - Urdaci, M. C.

PY - 2001

Y1 - 2001

N2 - A limited number of antibiotics can be used against Helicobacter pylori infection, and resistance jeopardizes the success of treatment. Therefore, a search for new agents is warranted. The use of probiotics to enhance gastrointestinal health has been proposed for many years, but the scientific basis of the prophylactic and therapeutic actions of probiotics has not yet been clearly delineated. Probiotic strain Bacillus subtilis 3, whose safety has previously been demonstrated, is known to have antagonistic properties against species of the family Enterobacteriaceae. In the present study, it was also found to inhibit H. pylori. The anti-H, priori activity present in the cell-free supernatant was not related to pH or organic acid concentration. It was heat stable and protease insensitive. At least two antibiotics, detected by thin-layer chromatography (Rf values, 0.47 and 0.85, respectively) and confirmed by high-performance liquid chromatographic analysis, were found to be responsible for this anti-H, pylori activity. All H. priori strains tested were sensitive to both compounds. One of these compounds was identified as amicoumacin A, an antibiotic with anti-inflammatory properties. MICs for H. priori determined in solid and liquid media ranged between 1.7 and 6.8 μg/ml and 0.75 and 2.5 μg/ml, respectively. The underestimation of MICs determined in solid medium may be due to physicochemical instability of the antibiotic under these test conditions. An additive effect between amicoumacin A and the nonamicoumacin antibiotic against H. pylori was demonstrated.

AB - A limited number of antibiotics can be used against Helicobacter pylori infection, and resistance jeopardizes the success of treatment. Therefore, a search for new agents is warranted. The use of probiotics to enhance gastrointestinal health has been proposed for many years, but the scientific basis of the prophylactic and therapeutic actions of probiotics has not yet been clearly delineated. Probiotic strain Bacillus subtilis 3, whose safety has previously been demonstrated, is known to have antagonistic properties against species of the family Enterobacteriaceae. In the present study, it was also found to inhibit H. pylori. The anti-H, priori activity present in the cell-free supernatant was not related to pH or organic acid concentration. It was heat stable and protease insensitive. At least two antibiotics, detected by thin-layer chromatography (Rf values, 0.47 and 0.85, respectively) and confirmed by high-performance liquid chromatographic analysis, were found to be responsible for this anti-H, pylori activity. All H. priori strains tested were sensitive to both compounds. One of these compounds was identified as amicoumacin A, an antibiotic with anti-inflammatory properties. MICs for H. priori determined in solid and liquid media ranged between 1.7 and 6.8 μg/ml and 0.75 and 2.5 μg/ml, respectively. The underestimation of MICs determined in solid medium may be due to physicochemical instability of the antibiotic under these test conditions. An additive effect between amicoumacin A and the nonamicoumacin antibiotic against H. pylori was demonstrated.

UR - http://www.scopus.com/inward/record.url?scp=0034770090&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034770090&partnerID=8YFLogxK

U2 - 10.1128/AAC.45.11.3156-3161.2001

DO - 10.1128/AAC.45.11.3156-3161.2001

M3 - Article

C2 - 11600371

AN - SCOPUS:0034770090

VL - 45

SP - 3156

EP - 3161

JO - Antimicrobial Agents and Chemotherapy

JF - Antimicrobial Agents and Chemotherapy

SN - 0066-4804

IS - 11

ER -